{{Short description|Combination antibiotic medication}} {{Infobox drug | type = combo | component1 = Ticarcillin | class1 = β-lactam antibiotic | component2 = Clavulanic acid | class2 = β-lactamase inhibitor
<!-- Clinical data --> | tradename = Timentin | Drugs.com = | MedlinePlus = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_category= | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> | legal_US = Rx-only | legal_status = | routes_of_administration = Injection
<!-- Identifiers --> | CAS_number = 86482-18-0 | ATCvet = | ATC_prefix = <!-- 'none' if uncategorised --> | ATC_suffix = | PubChem = | DrugBank = }}
'''Ticarcillin/clavulanic acid''', or '''co-ticarclav''', is a combination antibiotic consisting of ticarcillin, a β-lactam antibiotic, and clavulanic acid, a β-lactamase inhibitor. This combination results in an antibiotic with an increased spectrum of action and restored efficacy against ticarcillin-resistant bacteria that produce certain β-lactamases.<ref>{{cite journal | vauthors = Sutherland R | title = Beta-lactamase inhibitors and reversal of antibiotic resistance | journal = Trends in Pharmacological Sciences | volume = 12 | issue = 6 | pages = 227–232 | date = June 1991 | pmid = 2048218 | doi = 10.1016/0165-6147(91)90557-9 }}</ref><ref>[https://www.gsk.com.au/resources.ashx/prescriptionmedicinesproductschilddataproinfo/330/FileName/B929FC5BCDE9FCCA9E1EFCADA45F6E91/PI_Timentin.pdf GlaxoSmithKline. Date of Revision: February 7, 2014]</ref>
==References== {{reflist}}
{{DEFAULTSORT:Ticarcillin clavulanic acid}} Category:Combination antibiotics
{{antibiotic-stub}}